Skip to Main Content

Author Details

Alejandra Bruna
CRUK Cambridge Institute, University of Cambridge
2002
49
25
PMIDPaper TitleJournal TitlePublished Year
36426578MiR-182-3p targets TRF2 and impairs tumor growth of triple-negative breast cancer.EMBO Mol Med2023
37499655FOXC2 promotes vasculogenic mimicry and resistance to anti-angiogenic therapy.Cell Rep2023
36880458RANK is a poor prognosis marker and a therapeutic target in ER-negative postmenopausal breast cancer.EMBO Mol Med2023
35107878Anti-tumoural activity of the G-quadruplex ligand pyridostatin against BRCA1/2-deficient tumours.EMBO Mol Med2022
35663403Wnt Signaling in the Breast: From Development to Disease.Front Cell Dev Biol2022
36071033High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER<sup>+</sup> breast cancer.Nat Commun2022
35921524Identification of a Molecularly-Defined Subset of Breast and Ovarian Cancer Models that Respond to WEE1 or ATR Inhibition, Overcoming PARP Inhibitor Resistance.Clin Cancer Res2022
36376284Author Correction: High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER<sup>+</sup> breast cancer.Nat Commun2022
34189473Metabolic imaging with hyperpolarized [1-<sup>13</sup>C] pyruvate in patient-derived preclinical mouse models of breast cancer.STAR Protoc2021
33808071The Promise of Patient-Derived Preclinical Models to Accelerate the Implementation of Personalised Medicine for Children with Neuroblastoma.J Pers Med2021
33932331Deciphering the signaling network of breast cancer improves drug sensitivity prediction.Cell Syst2021
33723394PI3K activation promotes resistance to eribulin in HER2-negative breast cancer.Br J Cancer2021
34518533DNA methylation landscapes of 1538 breast cancers reveal a replication-linked clock, epigenomic instability and cis-regulation.Nat Commun2021
34680436Predicting Cancer Drug Response In Vivo by Learning an Optimal Feature Selection of Tumour Molecular Profiles.Biomedicines2021
32220884Genetic Alterations in the PI3K/AKT Pathway and Baseline AKT Activity Define AKT Inhibitor Sensitivity in Breast Cancer Patient-derived Xenografts.Clin Cancer Res2020
32005967Author Correction: ARID1A influences HDAC1/BRD4 activity, intrinsic proliferative capacity and breast cancer treatment response.Nat Genet2020
31913353ARID1A influences HDAC1/BRD4 activity, intrinsic proliferative capacity and breast cancer treatment response.Nat Genet2020
32747825Landscape of G-quadruplex DNA structural regions in breast cancer.Nat Genet2020
32976773Metabolic Imaging Detects Resistance to PI3Kα Inhibition Mediated by Persistent FOXM1 Expression in ER<sup>+</sup> Breast Cancer.Cancer Cell2020
30867590Dynamics of breast-cancer relapse reveal late-recurring ER-positive genomic subgroups.Nature2019
31213465Chromosome 12p Amplification in Triple-Negative/<i>BRCA1-</i>Mutated Breast Cancer Associates with Emergence of Docetaxel Resistance and Carboplatin Sensitivity.Cancer Res2019
31273933Chlorambucil targets BRCA1/2-deficient tumours and counteracts PARP inhibitor resistance.EMBO Mol Med2019
29304755Computational approach to discriminate human and mouse sequences in patient-derived tumour xenografts.BMC Genomics2018
30022119Shieldin complex promotes DNA end-joining and counters homologous recombination in BRCA1-null cells.Nat Cell Biol2018
30137431SOX4 can redirect TGF-β-mediated SMAD3-transcriptional output in a context-dependent manner to promote tumorigenesis.Nucleic Acids Res2018
30377213A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation.EMBO Mol Med2018
30507376Global transcriptional analysis identifies a novel role for SOX4 in tumor-induced angiogenesis.Elife2018
29635390RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer.Ann Oncol2018
29691252High USP6NL Levels in Breast Cancer Sustain Chronic AKT Phosphorylation and GLUT1 Stability Fueling Aerobic Glycolysis.Cancer Res2018
29795445MAP3K1 and MAP2K4 mutations are associated with sensitivity to MEK inhibitors in multiple cancer models.Cell Res2018
28912576Interrogating open issues in cancer medicine with patient-derived xenografts.Nat Rev Cancer2017
28104906Interrogating open issues in cancer precision medicine with patient-derived xenografts.Nat Rev Cancer2017
28420412Intersect-then-combine approach: improving the performance of somatic variant calling in whole exome sequencing data using multiple aligners and callers.Genome Med2017
29092942PDX-MI: Minimal Information for Patient-Derived Tumor Xenograft Models.Cancer Res2017
28729482BRCA1 and BRCA2 tumor suppressors protect against endogenous acetaldehyde toxicity.EMBO Mol Med2017
27641504A Biobank of Breast Cancer Explants with Preserved Intra-tumor Heterogeneity to Screen Anticancer Compounds.Cell2016
28381438Modeling Breast Cancer Intertumor and Intratumor Heterogeneity Using Xenografts.Cold Spring Harb Symp Quant Biol2016
27702751Patient-derived tumour xenografts for breast cancer drug discovery.Endocr Relat Cancer2016
25470049Dynamics of genomic clones in breast cancer patient xenografts at single-cell resolution.Nature2015
26245370Corrigendum: Progesterone receptor modulates ERα action in breast cancer.Nature2015
26686634Context-Specific Effects of TGF-β/SMAD3 in Cancer Are Modulated by the Epigenome.Cell Rep2015
26180079Maintaining Tumor Heterogeneity in Patient-Derived Tumor Xenografts.Cancer Res2015
22968701TGFβ induces the formation of tumour-initiating cells in claudinlow breast cancer.Nat Commun2012
21337521ZNF703 is a common Luminal B breast cancer oncogene that differentially regulates luminal and basal progenitors in human mammary epithelium.EMBO Mol Med2011
19851279Stem cell signaling in newly diagnosed, antipsychotic-naive subjects with nonaffective psychosis.Mol Psychiatry2009
17292826High TGFbeta-Smad activity confers poor prognosis in glioma patients and promotes cell proliferation depending on the methylation of the PDGF-B gene.Cancer Cell2007
14609950Glucocorticoid receptor-JNK interaction mediates inhibition of the JNK pathway by glucocorticoids.EMBO J2003
12941380Neuroprotective action of flavopiridol, a cyclin-dependent kinase inhibitor, in colchicine-induced apoptosis.Neuropharmacology2003
12355714Glucocorticoid receptor antagonism of AP-1 activity by inhibition of MAPK family.Ernst Schering Res Found Workshop2002
  • 1 - 49 of 49

Recommended Authors

Rohan Bareja
Case Western Reserve University
Career Start Year 2017
Number of shared co-authors 2
Sahil Seth
The University of Texas MD Anderson Cancer Center
Career Start Year 2014
Number of shared co-authors 7
Andrew Goodspeed
University of Colorado Denver | Anschutz Medical Campus
Career Start Year 2013
Number of shared co-authors 1
Daniel J McGrail
Center for Immunotherapy and Precision Immuno-Oncology, Cleveland Clinic
Career Start Year 2012
Number of shared co-authors 1
Aleksandra M Michalowski
Center for Cancer Research, National Cancer Institute
Career Start Year 2010
Number of shared co-authors 0
Frederick S Vizeacoumar
College of Medicine, University of Saskatchewan
Career Start Year 2010
Number of shared co-authors 1
Sander R van Hooff
Princess Maxima Center for Pediatric Oncology
Career Start Year 2008
Number of shared co-authors 5
David A Quigley
University of California-San Francisco
Career Start Year 2008
Number of shared co-authors 6
Rut Klinger
UCD Conway Institute, University College Dublin
Career Start Year 2006
Number of shared co-authors 2
Christopher A Bristow
The University of Texas MD Anderson Cancer Center
Career Start Year 2005
Number of shared co-authors 5
Tuan Zea Tan
Cancer Science Institute of Singapore, National University of Singapore
Career Start Year 2005
Number of shared co-authors 3
Kris C Wood
Duke University
Career Start Year 2005
Number of shared co-authors 3
Jonathan Chou
University of California san francisco
Career Start Year 2005
Number of shared co-authors 4
Joshy George
Peter MacCallum Cancer Centre
Career Start Year 2005
Number of shared co-authors 5
Laura M Heiser
Oregon Health Sciences University
Career Start Year 2005
Number of shared co-authors 9
Benjamin Haibe-Kains
Princess Margaret Cancer Centre, University Health Network
Career Start Year 2004
Number of shared co-authors 8
Xiaohu Zhang
National Center for Advancing Translational Sciences
Career Start Year 2003
Number of shared co-authors 1
Elena Ivanova
Dana-Farber Cancer Institute
Career Start Year 2003
Number of shared co-authors 1
Aik Choon Tan
Huntsman Cancer Institute, The University of Utah
Career Start Year 2003
Number of shared co-authors 2
David W Cescon
Princess Margaret Cancer Centre
Career Start Year 2003
Number of shared co-authors 4
Joel S Parker
Lineberger Cancer Center, University of North Carolina
Career Start Year 2002
Number of shared co-authors 4
Joshua Chuck Harrell
Virginia Commonwealth University
Career Start Year 2002
Number of shared co-authors 2
Darran P O'Connor
UCD Conway Institute, University College Dublin
Career Start Year 2001
Number of shared co-authors 6
Tobias Sj??blom
Uppsala University
Career Start Year 1999
Number of shared co-authors 0
Francesca M Buffa
University of Oxford
Career Start Year 1998
Number of shared co-authors 1
Jun Yao
The University of Texas MD Anderson Cancer Center
Career Start Year 1997
Number of shared co-authors 4
William M Gallagher
All-Island Cancer Research Institute, UCD Conway Institute, University College Dublin
Career Start Year 1996
Number of shared co-authors 10
Kornelia Polyak
Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School
Career Start Year 1991
Number of shared co-authors 11
Ben Ho Park
Vanderbilt University Medical Center
Career Start Year 1990
Number of shared co-authors 1
John W M Martens
Erasmus Medical Center (MC) Cancer Institute
Career Start Year 1989
Number of shared co-authors 13

Collaborators

Carlos Caldas
Cancer Research UK Cambridge Institute, University of Cambridge
Co-authored papers 36
Oscar M Rueda
University of Cambridge
Co-authored papers 22
Jos Jonkers
Oncode Institute, Netherlands Cancer Institute
Co-authored papers 6
Stephen-John Sammut
Co-authored papers 5
Samuel Aparicio
University of British Columbia
Co-authored papers 5
Rodrigo Dienstmann
Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus
Co-authored papers 5
José Baselga
Co-authored papers 4
Jason S Carroll
Co-authored papers 4
Annette T Byrne
Royal College of Surgeons in Ireland (RCSI)
Co-authored papers 3
Daniel S Peeper
Netherlands Cancer Institute
Co-authored papers 3
J. Carl Barrett
Oncology R&D
Co-authored papers 3
Livio Trusolino
Candiolo Cancer Institute - FPO IRCCS
Co-authored papers 3
Michael T Lewis
Baylor College of Medicine
Co-authored papers 3
Enzo Medico
Candiolo Cancer Institute, Fondazione del Piemonte per l'Oncologia (FPO) - IRCCS
Co-authored papers 3
Elisabetta Marangoni
Co-authored papers 3
Emilie Vinolo
CNRS URA 5
Co-authored papers 3
Kristel Kemper
Oncode Institute, The Netherlands Cancer Institute
Co-authored papers 3
Els Hermans
Netherlands Cancer Institute
Co-authored papers 3
Fr??d??ric Amant
Netherlands Cancer Institute
Co-authored papers 3
Andrea Bertotti
Candiolo Cancer Institute - FPO IRCCS
Co-authored papers 3
Zhongwu Lai
Oncology R&D
Co-authored papers 3
Hans Clevers
Princess Maxima Center for Pediatric Oncology
Co-authored papers 2
Lacey E Dobrolecki
Co-authored papers 2
Alana L Welm
Huntsman Cancer Institute, University of Utah
Co-authored papers 2
Kosuke Yusa
Wellcome Sanger Institute
Co-authored papers 2
Isabel T Rubio
Clinica Universidad de Navarra, Cancer Center Universidad de Navarra
Co-authored papers 2
Nuria Lopez-Bigas
Universitat Pompeu Fabra
Co-authored papers 2
Christina Curtis
Stanford University School of Medicine
Co-authored papers 2
Gordon B Mills
Knight Cancer Institute, Oregon Health and Sciences University
Co-authored papers 2
Abel Gonzalez-Perez
Universitat Pompeu Fabra
Co-authored papers 2
Release 1.2